Business Wire

STEMCELL-TECHNOLOGIES

Share
STEMCELL Technologies Opens New Office and Laboratories in Cambridge, UK

STEMCELL Technologies UK has recently celebrated the grand opening of their Cambridge-based facility. Founded by Dr. Allen Eaves, STEMCELL provides specialized reagents and tools that support research on cancer and other diseases, as well as cell therapy and regenerative medicine globally. Cambridge is a leading global hub for stem cell research. This, combined with its proximity to STEMCELL’s customers in the UK and Europe, makes the location a natural choice for continued investment by the company.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170131005406/en/

STEMCELL recently took possession of an 18,000 square foot building located in the Cambridge Research Park. STEMCELL has now consolidated existing UK staff into the facility, which at full capacity will house a substantial Research and Development group, as well as Sales, Marketing and other support staff.

A major focus of the new facility will be a state-of-the-art Education and Teaching Lab. STEMCELL offers several standard and customized training courses and workshops, which are currently hosted within collaborating academic lab facilities. The multi-day, interactive courses are designed to help researchers develop expertise in protocols and techniques supported by STEMCELL’s products. Several of these world-class courses will soon be offered in the new Cambridge facility, making them more accessible to researchers in the UK and Europe.

Dr. Allen Eaves, CEO and President of STEMCELL Technologies, commented:

STEMCELL is committed to driving the advancement of science by offering the highest quality products and services to support scientists with their research. We are thrilled to be officially opening our new Cambridge office, including our Research and Development labs and Education Centre. STEMCELL has seen fantastic growth, and this facility will take us to the next level in supporting medical sciences research globally, as well as open our doors to the incredible biomedical expertise in the UK and Europe.”

About STEMCELL Technologies
As a company of Scientists Helping Scientists, STEMCELL Technologies is committed to providing high-quality reagents, tools and services supporting life sciences research. Scientists performing stem cell, immunology, cancer, regenerative medicine and cellular therapy research rely on STEMCELL’s cell culture media, cell separation products, instruments, accessory reagents, and scientific services. Driven by science and a passion for quality, over 2500 STEMCELL products are available to researchers worldwide.

Contact:

STEMCELL Technologies
Andrew Booth, Chief Commercial Officer
public.relations@stemcell.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Budweiser Kicks Off New “Celebration in the Making” Global Platform for FIFA Club World Cup 2025™6.6.2025 10:00:00 CEST | Press release

Brand Returns “Bring Home The Bud” Campaign, Debuts New Film Set to AC/DC’s “Thunderstruck” to Remind Fans that Bud is the Beer of Celebration Throughout the Tournament Today, Budweiser (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD) unveils its new global platform “Celebration in the Making” and full campaign details as the Official Global Beer Sponsor of the FIFA Club World Cup 2025™. This summer, as football supporters around the globe bring their energy to the groundbreaking tournament, Budweiser will be there to elevate celebrations at every stage – from the opening touch to the final whistle, and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606379419/en/ Budweiser Kicks Off New “Celebration in the Making” Global Platform for FIFA Club World Cup 2025™ To inspire celebrations from the start, Budweiser is officially kicking off the platform with a new film set to an iconic score, and announces the return of its

SES Announces Appointment of New CFO6.6.2025 08:30:00 CEST | Press release

Elisabeth Pataki, a progressive finance executive with over 20 years of experience at various publicly listed multi-national aerospace and defence companies, will strengthen SES’s Leadership Team as new CFO SES today announced its Board of Directors has appointed Elisabeth (Lisa) Pataki as Chief Financial Officer (CFO), effective 16 June 2025. Lisa is a progressive finance executive with over 20 years of experience at various publicly listed multi-national aerospace and defence companies with strong background in company transformation and investment strategies. She will succeed Sandeep Jalan who has been SES’s CFO since May 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250605243814/en/ Lisa Pataki The SES Board acknowledges Sandeep’s contribution to SES and wishes him success in future endeavours. Lisa will work closely with Sandeep to ensure a smooth handover before he leaves on 31 July 2025. “I would like to thank

RAD 2025: Long-Term Data on Nemluvio® (nemolizumab) Demonstrate its Favorable Safety Profile and Sustained and Increased Improvements in Itch and Skin Lesions in Patients With Atopic Dermatitis up to Two Years6.6.2025 07:00:00 CEST | Press release

New interim two-year data from a long-term extension study of Nemluvioin atopic dermatitis reinforce its rapid onset of action and demonstrate its lasting impact across multiple clinical and patient reported outcomes including itch and skin lesions1 Results build on data from the phase III ARCADIA program, showing Nemluvio’s consistent safety profile and sustained and increased improvements in efficacy outcomes in atopic dermatitis patients during prolonged treatment up to two years1,2 Two-year data from a long-term extension study of Nemluvio in prurigo nodularis will also be presented later in June at the International Congress of Dermatology Galderma (SIX: GALD) today announced two-year data from a new interim analysis of a long-term extension study investigating the safety and efficacy of Nemluvio in moderate-to-severe atopic dermatitis. The data show that Nemluvio is well tolerated, with no new safety signals identified, reinforcing its rapid onset of action and demonstrating sust

BGO Announces US$5.1 Billion Capital Raise for Its Asia Value-Add Real Estate Strategy, Marking Largest Closed-End Fundraise in Firm’s History5.6.2025 22:00:00 CEST | Press release

BGO today announced the final close of BentallGreenOak Asia IV (“BGO Asia Fund IV” or the “Fund”), its flagship Asia-focused value-add real estate strategy, raising over US$5.1 billion in total capital commitments for the Fund and co-investment sidecars. The Fund represents the largest closed-end capital raise in BGO’s history, underscoring the firm’s history and reputation as a premier global real estate investment manager in Asian markets. BGO Asia Fund IV targets value-add opportunities in office, hospitality, and logistics assets across Japan, South Korea, Australia, and Singapore. Japan represents a central pillar of our investment strategy, driven by regulatory reforms and corporate governance shifts that are catalyzing an estimated US$3 trillion in non-core asset divestitures. “Japan is undergoing a profound transformation, and we see strong, sustained tailwinds across the region,” said Fred Schmidt, Managing Partner and Chairman of Asia, BGO. “Tokyo is one of the world’s larges

PIF and FIFA forge partnership for FIFA Club World Cup 2025™5.6.2025 19:00:00 CEST | Press release

PIF joins inaugural FIFA Club World Cup™ ahead of kick-off on June 14 in Miami The partnership expands PIF’s global footprint in sports and reflects a shared commitment with FIFA to fuel growth and engagement in football FIFA Club World Cup 2025™ will make history, redefining club football and bringing 32 of the world’s best clubs together for the first time PIF and FIFA today announced PIF as an official partner of FIFA Club World Cup 2025™, which will take place in the U.S. from June 14 to July 13, 2025. The partnership reflects FIFA and PIF’s shared vision to enable greater participation in sports by unlocking new opportunities, fostering innovation and engaging fans around the world. With a focus on youth, the partnership will provide opportunities for young people, supporting FIFA in its efforts to engage and inspire at a grassroots level. The new FIFA Club World Cup 2025™ marks a fresh chapter for club football on the global stage. It will feature 32 of the world’s top football c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye